AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesRecurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Secondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Childhood Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- Drug: HDAC inhibitor AR-42Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 13
- Registration Number
- NCT01798901
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia FollowingAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Acute Myeloid LeukemiaMyelodysplastic SyndromeAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 34
- Registration Number
- NCT01174888
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Phase 2
Terminated
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: lintuzumab
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 7
- Registration Number
- NCT00997243
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath